<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917016</url>
  </required_header>
  <id_info>
    <org_study_id>0195-19-ASF</org_study_id>
    <nct_id>NCT04917016</nct_id>
  </id_info>
  <brief_title>B-HCG Levels in Women Diagnosed With Retained Products of Conception</brief_title>
  <official_title>B-HCG Levels in Women Undergoing Hysteroscopy for Removal of Retained Products of Conception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retained Products of Conception (RPOC) is a condition where gestational tissue remains in the&#xD;
      uterus after birth or after a surgical or medical abortion. This condition may cause&#xD;
      significant bleeding, infection, and long-term intrauterine adhesions associated with&#xD;
      fertility problems and pregnancy complications (Asherman's syndrome). RPOC are diagnosed&#xD;
      according to the clinical and ultrasound findings (such as an echogenic foci in the uterine&#xD;
      cavity with Doppler blood flows). However, the diagnosis of RPOC by clinic and ultrasound&#xD;
      characteristics is inaccurate and false positive results are reported in up to 40% of women&#xD;
      undergoing a surgical procedure for RPOC removal (most often by hysterosocpy). However,&#xD;
      surgery also carries a risk of complications and intrauterine infections. Therefore, the need&#xD;
      arises for additional tools to improve the diagnosis available today in order to minimize the&#xD;
      need for surgical procedures as much as possible.&#xD;
&#xD;
      The production and secretion of the B-HCG occurs in the placenta and begins after blastocyst&#xD;
      implantation. The B-HCG levels increase in other placental pathologies such as gestational&#xD;
      trophoblastic disease (GTD). Accordingly, the investigators hypothesized that in cases of&#xD;
      placental remnants a secretion of B-HCG may be detected and quantified.&#xD;
&#xD;
      In this prospective, non-interventional study the investigators' aim is to examine whether&#xD;
      B-HCG can be used as a marker for detecting placental remnants, compared to the currently&#xD;
      accepted sonographic method. For this purpose, the investigators will examine the levels of&#xD;
      B-HCG in participants undergoing hysteroscopy for removal of RPOC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>B-HCG levels</measure>
    <time_frame>From randomization to the day of surgery, assessed up to 3 months</time_frame>
    <description>Plasma levels of B-HCG measured in mU/mL in women undergoing hysteroscopy for removal of RPOC</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Retained Products of Conception</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Women undergoing hysteroscopy for removal of RPOC</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Plasma B-HCG levels</intervention_name>
    <description>Blood sample</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women &gt;18 years admitted for hysteroscopy for RPOC removal following delivery of abortion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Admitted for hysteroscopy for RPOC removal following delivery&#xD;
&#xD;
          -  Admitted for hysteroscopy for RPOC removal following abortion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low suspicion of RPOC by clinical or ultrasound examination.&#xD;
&#xD;
          -  No pathology specimen available.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noam Smorgick, MD Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shamir Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shamir Medical Center</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <zip>70200</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome--one century later. Fertil Steril. 2008 Apr;89(4):759-79. doi: 10.1016/j.fertnstert.2008.02.096. Review.</citation>
    <PMID>18406834</PMID>
  </results_reference>
  <results_reference>
    <citation>Barel O, Krakov A, Pansky M, Vaknin Z, Halperin R, Smorgick N. Intrauterine adhesions after hysteroscopic treatment for retained products of conception: what are the risk factors? Fertil Steril. 2015 Mar;103(3):775-9. doi: 10.1016/j.fertnstert.2014.11.016. Epub 2014 Dec 17.</citation>
    <PMID>25527235</PMID>
  </results_reference>
  <results_reference>
    <citation>Smorgick N, Barel O, Fuchs N, Ben-Ami I, Pansky M, Vaknin Z. Hysteroscopic management of retained products of conception: meta-analysis and literature review. Eur J Obstet Gynecol Reprod Biol. 2014 Feb;173:19-22. doi: 10.1016/j.ejogrb.2013.11.020. Epub 2013 Dec 1. Review.</citation>
    <PMID>24332096</PMID>
  </results_reference>
  <results_reference>
    <citation>Smorgick N, Krakov A, Maymon R, Betser M, Tovbin J, Pansky M. Postpartum Retained Products of Conception: A Novel Approach to Follow-Up and Early Diagnosis. Ultraschall Med. 2018 Dec;39(6):643-649. doi: 10.1055/s-0043-113817. Epub 2017 Sep 21.</citation>
    <PMID>28934813</PMID>
  </results_reference>
  <results_reference>
    <citation>van den Bosch T, Daemen A, Van Schoubroeck D, Pochet N, De Moor B, Timmerman D. Occurrence and outcome of residual trophoblastic tissue: a prospective study. J Ultrasound Med. 2008 Mar;27(3):357-61.</citation>
    <PMID>18314513</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assaf-Harofeh Medical Center</investigator_affiliation>
    <investigator_full_name>Assaf Harofeh MC</investigator_full_name>
    <investigator_title>Noam Smorgick MD, Director of Minimally Invasive Gynecologic Surgery</investigator_title>
  </responsible_party>
  <keyword>Hysteroscopy</keyword>
  <keyword>Ultrasound</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

